Aptamer Sciences Inc (KOSDAQ:291650)
South Korea
· Delayed Price · Currency is KRW 1,427.00
+22.00 (1.57%)
At close: Mar 9, 2026
Aptamer Sciences Revenue
In the year 2024, Aptamer Sciences had annual revenue of 1.08B KRW with 345.26% growth. Aptamer Sciences had revenue of 920.07M in the quarter ending December 31, 2024, with 5,471.58% growth.
Revenue
1.08B
Revenue Growth
+281.58%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
57.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08B | 839.63M | 345.26% |
| Dec 31, 2023 | 243.19M | -115.07M | -32.12% |
| Dec 31, 2022 | 358.25M | 88.98M | 33.04% |
| Dec 31, 2021 | 269.28M | 40.77M | 17.84% |
| Dec 31, 2020 | 228.51M | -179.09M | -43.94% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EyeGene | 4.10B |
| NGeneBio | 9.98B |
| SunBio,Inc. | 2.17B |
| HLB Pep | 4.89B |
| PanGen Biotech | 15.27B |
| Ark Solutions | 21.50B |
| J2KBIO | 31.12B |
| CHA Vaccine Research Institute | 158.62M |